From Design to Impact: MilliporeSigma’s First Climate-Neutral Manufacturing Facility
NORTHAMPTON, MA / ACCESS Newswire / September 22, 2025 / MilliporeSigma, the U.S. and Canada Life Science business of Merck...
Day: September 22, 2025
iTolerance, Inc. Appoints Sandra Cohen Kalter to Strategic Advisory Group
Legal & regulatory executive with extensive expertise in FDA law and regulatory leadership for one of the world's leading medical...
Medical Care Technologies Inc. Introduces AI Breakthrough for Squamous Cell Carcinoma Detection
MESA, ARIZONA / ACCESS Newswire / September 22, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a significant...
Medical Care Technologies Inc. Introduces AI Breakthrough for Squamous Cell Carcinoma Detection
MESA, ARIZONA / ACCESS Newswire / September 22, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a significant...
The Midwife & More Celebrates Historic Milestone as First Certified Nurse Midwife Granted Hospital Privileges at Los Robles Hospital
THOUSAND OAKS, CA / ACCESS Newswire / September 22, 2025 / After months of anticipation, The Midwife & More proudly...
MentalHealth.com Acquires Therapy.ai to Advance Person-Centered Systems of Care
SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2025 / MentalHealth.com today announced its acquisition of Therapy.ai, a move...
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with...
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of...
NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice Dr. Raymond Turner Dr. Turner...
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD
New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challengesSEATTLE and VANCOUVER,...
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based...
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which...
Jushi Holdings Inc. Announces Favorable Modifications to Existing Manassas, VA Mortgage
Company received $4,000,000 of additional loan proceeds Maturity date extended to September 18, 2030 Capital infusion bolsters balance sheet for...
FOXO TECHNOLOGIES INC. ANNOUNCES CLOSING OF VECTOR BIOSOURCE INC. ACQUISITION
WEST PALM BEACH, FL, Sept. 22, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTCID: FOXO) (“FOXO” or the “Company”), announces the closing of...
New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences’ Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach
Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued market...
AMN Healthcare Launches $400.0 Million Offering of Senior Notes
DALLAS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), announced today that its wholly owned subsidiary,...
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key...
24/7 Market News: Kraig Labs Targets Eco Luxury Spider Silk Apparel Market
Potential Multi-Billion Dollar as Sample Deliveries NearDENVER, Sept. 22, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated...
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian...